• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169850 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
( {  s) x" K. F; s: F
) L' s9 b+ s6 m6 d& y4 d" ]9 S
( P" a8 a! r- Q, ~Sub-category:1 d/ f* K+ H. L
Molecular Targets
; b" _2 `# O4 A$ r5 D& ~$ L
4 X" U5 U4 X4 U! p5 [. U1 b$ n/ e
1 R, E# W7 m  T0 _$ m1 SCategory:
& ?/ n1 p9 ^4 nTumor Biology $ m7 T& R" n7 b- C. t8 J

4 s' f. G3 p- K) @0 O
3 H# C8 e% X* @: r3 `+ tMeeting:- }$ k9 Y! c6 U4 I
2011 ASCO Annual Meeting
. q- C* o: }9 J% ^8 f, a! |  @7 N  |0 z: k8 g( r; ^

' Y: m  F2 f* e3 s4 f( M: U9 PSession Type and Session Title:0 f, ^3 }4 q# y6 [& j
Poster Discussion Session, Tumor Biology 7 L' r5 U; }: q  G. [5 x
) h0 Y% V% P& x* v5 `
( k. W+ D0 y/ r
Abstract No:- |* d$ E% ?  r/ K! @9 J; M0 P9 t
10517
. v3 e0 a+ I# j8 p6 n* {3 B* B1 s0 G' S1 ?  t

# c* e- M% G' R  DCitation:) A1 K# \* T% X7 r' P) g
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 {! B- b: {* |: P( |
4 Q1 {$ O" C3 H6 w) _

6 p) ]8 S6 o4 P2 F% zAuthor(s):
9 k: O0 j3 [5 X" ~8 B2 P! }J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
, Z1 A7 F* b4 A# X
% ^, s$ p; M9 z5 l
% Q+ P- i3 Q2 U0 i3 _& c0 i% b9 P$ a. C8 p, ~
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.. j, U* c1 Q- g+ Q& ]! X

& S9 U0 G' k0 i# ^* d1 \+ A/ JAbstract Disclosures- M7 W& W# D. Y
, [: _5 n6 K; Y! {4 v- V+ s
Abstract:, d; d3 u9 `# R0 a8 t9 v+ N

" t/ V' m5 c: W/ T7 N5 R+ z( }$ d  v
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.5 W6 f- f* q) k' ?: y
" ~4 @7 e% i$ b3 W, B9 x8 B! E9 A1 O

0 `4 F: J$ {! C. Y0 t
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
8 E) {1 t' B' K! m3 O3 Y$ ~( R没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
" }8 w, D* P, b9 c2 }
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
7 q% u4 Z) X0 Y4 _) V3 ?易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。; G  f7 ~8 y7 S' S
ALK一个指标医院要900多 ...

( y6 b4 v5 x4 W5 z! z5 L平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?; A; z0 [6 V$ x, o! u% b8 j2 G8 `
2 `* A9 ?) x3 r& [3 i
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表